Treatment-related adverse events were assessed according to the Common Terminology Criteria for Adverse Events version 5.0; entrectinib elicited grade 4 neutropenia, grade 3 leukopenia, grade 2 increased alanine aminotransferase, increased serum creatinine, increased aspartate aminotransferase, dysgeusia and grade 1 anemia, increased alkaline phosphatase, vertigo, and dizziness. The gene discussed is GPT; the disease is anemia (phenotype).